(MedPage Today) — NEW ORLEANS — The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in patients with or at high risk for atherosclerotic cardiovascular disease, the phase III CORALreef Lipids…
Source link : https://www.medpagetoday.com/meetingcoverage/aha/118418
Author :
Publish date : 2025-11-10 17:35:00
Copyright for syndicated content belongs to the linked Source.
